Mariana Polyvkan

Mariana Polyvkan

Auto-generated profile, based on publicly available information

Mariana Polyvkan

Ivano-Frankivsk National Medical University of the Ministry of Health of Ukraine, Ivano-Frankivsk, Ukraine

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2026 in Reports of Morphology
Verified
Journal Article
Open access
HKH. B. Kulynych
H. B. Kulynych
SHS. B. Herashchenko
S. B. Herashchenko
VFV. M. Fedorak
V. M. Fedorak
HYH. Yu. Yurah
H. Yu. Yurah
MPM. I. Polyvkan
M. I. Polyvkan
OAO. V. Atamanchuk
O. V. Atamanchuk
Combined chemotherapy regimens involving the concurrent administration of cisplatin and paclitaxel remain a standard approach for the treatment of many solid tumors; however, they are associated with a high incidence of neurotoxic complications. The central component of neurotoxicity remains insufficiently studied. The hippocampus is one of the most vulnerable structures of the central nervous system. Fragmentary data on the phasic nature, temporal dynamics, and morphofunctional correlates of central neurotoxicity with the simultaneous use of cisplatin and paclitaxel form a gap between the clinical manifestations of cognitive deficit and the results of most experimental models. The aim of this study was to characterize the temporal dynamics of morphological changes in the rat hippocampus following the concurrent administration of cisplatin and paclitaxel and to identify the key phases of central neurotoxicity development. Experimental studies were performed on adult male white inbred rats weighing 180-220 g. Morphological and morphometric changes in the hippocampus were evaluated on days 1, 7, 14, 28, 60, 90, and 120 after treatment using light microscopy and morphometric analysis of neuronal and glial elements. Statistical analysis was performed using one-way analysis of variance (ANOVA) and the Mann-Whitney U test. Concurrent administration of cisplatin and paclitaxel resulted in a phase-dependent pattern of hippocampal injury. In the early observation periods, edematous-dystrophic neuronal changes and disturbances of neuroglial interactions predominated. On days 7-14, progressive destructive processes were observed, while day 28 was characterized by the maximal level of morphological damage with pronounced disorganization of the pyramidal layer. In the late periods (60-120 days), signs of incomplete morphological repair were detected, including partial restoration of layer organization with persistent reactive glial changes. The obtained results indicate that the concurrent administration of cisplatin and paclitaxel leads to persistent structural alterations of the hippocampus, which may underlie cognitive disorders and substantiate the need for further investigation of neuroprotective strategies.

27 February 2026 in The Journal of V. N. Karazin Kharkiv National University, Series "Medicine"
Verified
Journal Article
Closed access
HKH.B. Kulynych
H.B. Kulynych
SHS.B. Herashchenko
S.B. Herashchenko
MOM.M. Ostrovskyi
M.M. Ostrovskyi
MPM.I. Polyvkan
M.I. Polyvkan
Background. Chemotherapy-induced peripheral neuropathy is a common complication of anticancer therapy with taxane- and platinum-based agents and is accompanied by persistent motor impairments that significantly limit the body’s functional capacity and reduce patients’ quality of life. Despite the clinical significance of motor deficits, their temporal dynamics and severity under concurrent administration of paclitaxel and cisplatin remain insufficiently studied. Purpose – to compare the temporal dynamics and severity of motor impairments in rats with chemotherapy-induced peripheral neuropathy following administration of paclitaxel, cisplatin, and their concurrent use over a 120-day observation period. Materials and Methods. The study was conducted on adult male inbred white rats, divided into four groups: intact control, paclitaxel (cumulative dose 8 mg/kg, intraperitoneally), cisplatin (cumulative dose 16 mg/kg, intraperitoneally), and a combination group. In the combination group, animals received cisplatin at 2 mg/kg and paclitaxel at 5 mg/kg once weekly for six weeks, providing a cumulative dose of 12 mg/kg for cisplatin and 30 mg/kg for paclitaxel. This regimen corresponded to standard clinical protocols of paclitaxel (175 mg/m²) and cisplatin (75 mg/m²) when adjusted for body surface area. Motor activity and coordination were assessed on days 1, 7, 14, 28, 60, 90, and 120 using the Open Field and Rotarod tests with a patented device for evaluating coordination and muscle endurance. Results. Chemotherapy-treated animals demonstrated persistent reductions in overall motor activity and coordination compared to the intact control group. Motor deficits developed from day 7 with paclitaxel, whereas cisplatin-induced impairments appeared as early as day 1. The most pronounced and long-lasting changes were observed under concurrent administration of paclitaxel and cisplatin, persisting throughout the 120-day observation period. Conclusions. Paclitaxel and cisplatin induce long-term motor deficits in an experimental model of chemotherapy-induced peripheral neuropathy, with combined administration resulting in the most severe impairments of coordination and activity. Behavioral tests such as Open Field and Rotarod provide informative tools for assessing the temporal dynamics and severity of motor dysfunction in neurotoxicity models.

5 June 2026 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Closed access
HKHaliia Kulynych
Haliia Kulynych
SHSerhii Herashchenko
Serhii Herashchenko
OAOksana Atamanchuk
Oksana Atamanchuk
MPMariana Polyvkan
Mariana Polyvkan
VFVolodymyr Fedorak
Volodymyr Fedorak
VPVasyl Pertsovych
Vasyl Pertsovych
Background. Paclitaxel is well known for its neurotoxicity, which affects both the peripheral and central nervous systems. In the hippocampus, this cytostatic agent disrupts neuroplasticity, induces glial activation, and may lead to cognitive impairment. Because in clinical practice most patients receive treatment against the background of already established neurological disorders, the search for agents capable of correcting post-toxic changes remains highly relevant.Vortioxetine, a multimodal serotonin modulator, influences synaptic transmission, neuroplasticity, and glutamatergic networks, making it potentially useful for restoring structures damaged by chemotherapy. At the same time, the effects of therapeutic administration of vortioxetine specifically after paclitaxel-induced toxicity in central nervous system regions remain insufficiently studied. Aim: To evaluate morphological changes in the rat hippocampus under conditions of therapeutic administration of vortioxetine after paclitaxel-induced neurotoxicity. Materials and Methods. The study was performed on sexually mature male inbred white rats (180–220 g) housed under standard vivarium conditions. Neurotoxicity was induced by paclitaxel administration (2 mg/kg, intraperitoneally, four injections every other day). The therapeutic effect was assessed following intragastric administration of vortioxetine (5 mg/kg, daily for 14 days), initiated after completion of the paclitaxel course. Functional status was evaluated using behavioral tests of mechanical and thermal sensitivity. Morphological and morphometric changes in the hippocampus (CA1 and CA3 regions) were analyzed on days 14, 28, 60, 90, and 120 using light microscopy after hematoxylin and eosin staining with digital morphometry. Statistical analysis was performed using ANOVA or the Mann-Whitney U test at p<0.05. All procedures complied with international ethical standards for laboratory animal research. Results. Therapeutic administration of vortioxetine after paclitaxel-induced neurotoxicity reduced the severity of hippocampal morphological damage and modified the temporal dynamics of recovery processes. As early as day 14, partial preservation of the pyramidal layer architecture in CA1-CA3 was observed against a background of moderate edema and limited glial reaction. During the peak toxic phase (day 28), the depth of tissue destruction was lower than in untreated animals, with preservation of neuronal nuclei and reduced areas of tissue homogenization. On days 60–90, reparative changes predominated, manifested by restoration of perikaryon contours, stabilization of glial elements, and gradual recovery of laminar organization. By day 120, nearly complete morphological repair of the hippocampus was observed. Morphometric analysis confirmed attenuation of toxic alterations: in the CA1 and CA3 regions, the areas of neuronal perikarya and nuclei were significantly increased, the nucleus-to-cytoplasm ratio was partially normalized, and neuronal density was higher compared with the untreated toxic group (p<0.05). Functional tests demonstrated that paclitaxel induced a persistent motor-sensory deficit. Under vortioxetine treatment, the severity of motor and sensory impairments was significantly lower, with partial compensation in later time points, consistent with morphological signs of the drug’s neuroprotective and reparative effects. Conclusions. Therapeutic administration of vortioxetine reduces toxic damage to the hippocampus and accelerates reparative processes after paclitaxel exposure. The drug may be considered a promising agent for post-toxic correction of central manifestations of chemotherapy-induced neurotoxicity.